Although there were only three simple dishes and one soup, Zhang Chen and Li Bozhan ate for an hour.

The two talked about chemical medicines, protein medicines, and then cell gene therapy, and finally expressed their views on small nucleic acid drugs, and now they are back to agriculture.

"Xiao Zhang, how confident are you to create a molecular farm?"

Li Bozhan remembered that Zhang Chen had said before that he would start working on the molecular farm in the future.

He was very interested in this area and had done some research before, but he did not continue in the end.

Molecular farms are much more complicated than soybean production. He believes that with the current level of biotechnology, they cannot achieve the expected results.

"I have plans to dabble in this field, but I'm not sure about how confident I'm still not sure."

Zhang Chen knows something now. He said he wanted to build this molecular farm before, but he saw that there were related products in the system that could be redeemed.

But he has to mass produce them, but he still doesn't know the specific difficulty.

Molecular farms are just a general term, and they are subdivided into many types, and the technological content is very different.

The simplest thing is of course to use gene editing to enhance the efficacy of some existing Chinese herbal medicines.

Going further, design certain compounds that can treat or prevent the corresponding diseases, and find ways to make them naturally synthesized in fruits or food crops, so as to achieve the purpose of preventing or even treating diseases.

Although such a method sounds simple, it is particularly difficult to do it.

The current level of technology is limited, and some complex compounds are difficult to synthesize in vitro even if they are artificially synthesized in vitro, let alone let alone let them synthesize naturally through plants.

This must be studied very thoroughly in this plant, and its various regulatory mechanisms and signal pathways must be clearly understood.

On this basis, it is also necessary to consider whether the compounds that need to be synthesized and whether they can be synthesized on this plant.

If it cannot be synthesized, it is necessary to study a different plant and continue to match it.

Plants have various characteristics and various types, and such scientific research tasks are extremely heavy.

Fortunately, bioinformatics has emerged, which is a brand new scientific research method.

Zhang Chen had already made preparations and could quickly get the team up when needed.

In addition, there are therapeutic proteins, therapeutic genes, etc., which can be produced with the help of plants.

The benefits of molecular farms are self-evident.

Just imagine, eating a banana can last for half an hour. Isn’t this effect fragrant?

Eating two grapes can relieve depression. Is this effect less than six?

But to achieve it, it is quite difficult. To be happy, you have to pay something.

Even a comparison like Zhang Chen requires hard work.

So he couldn't guarantee that he could do anything, but for everyone's happiness and points that should have belonged to him, he would definitely do his best.

Thinking of this, Zhang Chen said firmly: "Although I can't guarantee that it will succeed, I will try it. I guess after Lanyue 001 is launched, I will establish a project and carry out this research topic. Mr. Li, are you interested in participating?"

"I'm very interested. I must tell me then that I will bring the funds and people into the group!"

Li Bozhan should not be too interested.

He had long wanted to get involved in the molecular farm field, but he was weak at the beginning and was completely sorry for this mountain, so he could only settle for the second best and start soybean production.

Now with Zhang Chen's great help, he has no reason not to try it.

And the most important thing is that Zhang Chen has already dealt with the soybean production, so he has nothing to do.

"Haha, Mr. Li, you can bring people. I welcome them very much, but it's all right to bring money. I still have a lot of spare money, so I can still afford this little expense."

Zhang Chen was amused by Li Bozhan's statement and even wanted to bring funds to the group.

"Okay, which aspect do you plan to start first?" Li Bozhan said curiously.

"Forget it, which chemical drugs now have no side effects? I plan to start directly with protein. The difficulty is a bit more, but the advantage is that they are safe and the effect lasts for a long time."

Nowadays, chemical medicines on the market are basically taken every day, and there are still many side effects.

Protein medicine is only injected once every few weeks or even months, and gene therapy solves the problem at one time.

Gene therapy is simple in vitro pharmaceuticals, but it is difficult to make it naturally synthesized in plants, and there are too many problems involved.

And proteins need to be naturally synthesized in plants, which is a little bit clueful.

"Good thing, I think so too, so I'll wait for the good news."

Li Bozhan wiped his mouth and stood up and said.

"Okay, I will tell you the first time," Zhang Chen also stood up, "I will bring the lawyer here another day and sign an authorization agreement with you."

After the meal, the two agreed to go home.

The next day, September 2, today is a big day.

Chenyue Biotechnology Co., Ltd., a gene therapy drug with the product name Lanyue 001, will hold phase II clinical trials simultaneously in several hospitals across the country.

Phase II clinical trials are relatively critical.

Many companies can complete phase one clinical trials, but they cannot survive phase two clinical trials.

It’s not that the drug is not safe, but in fact, most drugs that can be approved by relevant departments for clinical trials or even complete phase one clinical trials will not have safety risks.

However, most companies have very limited funds and do not have certain economic strength, so the second phase clinical trials are really unsuccessful.

From early research and development to phase one clinical trials, the cost is not very large.

However, as the number of subjects increased tenfold in the first and second phases of the clinical trial, the costs to be borne immediately surged.

Therefore, many companies only make medicines for the first phase of the clinical stage. They choose to sell their intellectual property rights at this time and directly resell the results.

As long as the clinical data in the first phase is good enough, it will definitely be sold at a good price.

Then rely on this startup capital to create new glory and become bigger and stronger.

As a result, a very common phenomenon occurred. Many pharmaceutical companies carried out several drug research and development pipelines at the same time.

If any project can make its mark, go to clinical trials, or even last for phase I clinical trials.

Then you can quickly recover funds and revitalize other projects.

Many large pharmaceutical companies are also happy to take over such innovative drugs.

Several hundred million are just a little bit for them, what they lack is time.

These giants don’t have the time to start scientific research from scratch. If you have that time, it’s better to do more production and make some cash.

Spending money to buy phased results is a method that many major manufacturers are playing now.

Of course, there are also very powerful giants who directly choose to acquire small companies with scientific research results, which is another matter.

But Zhang Chen didn't have these messy ideas. He has been going to go public from the beginning.

Not short of money or technology, why not go public?

Early in the morning, Zhang Chen brought Zhang Yue and Tian Wenbin to Shaocheng People's Hospital.
Chapter completed!